结合分子及抗体药物偶联物和用途
By constructing anti-EGFR and anti-cMet binding molecules using small immunoglobulin single variable domains (ISVDs), the problems of insufficient penetration and targeting of existing drugs in tumor treatment are solved, achieving more efficient tumor killing and reduced off-target toxicity.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- VELAVIGO (SHANGHAI) LTD
- Filing Date
- 2024-11-22
- Publication Date
- 2026-07-17
AI Technical Summary
Existing EGFR and cMet dual-targeting antibody drugs have large molecular weights, making it difficult to penetrate tumor tissues, resulting in insufficient penetration and targeting in tumor treatment. Furthermore, conventional antibodies may cause off-target toxicity.
Using small immunoglobulin single variable domain (ISVD) as the binding molecule against EGFR and cMet, antibody-drug conjugates (ADCs) with excellent tumor targeting and endocytic activity were constructed. The tumor killing effect was further enhanced by conjugation or coupling with chemotherapeutic agents, toxins, radioactive elements, etc.
It achieves better tumor tissue penetration and targeting, reduces off-target toxicity, significantly increases killing activity against tumors with high EGFR and cMet expression density, has higher endocytosis efficiency and affinity, and reduces side effects.
Smart Images
Figure FT_1 
Figure FT_2 
Figure FT_3